FDA MedWatch - Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B): Strengthened warnings in product labeling

ROCKVILLE, Md., April 30, 2009--FDA notified healthcare professionals that after an ongoing safety review initiated in February 2008, the manufacturers of licensed botulinum toxin products will be required by FDA to strengthen warnings in product...

Comments

• Find It

• Recently Written

  • Eli Lilly’s Lechleiter Not Interested In Big Acquisitions
  • S&P May Pare Credit Ratings On Sanofi-Aventis
  • Bristol-Myers Squibb To Buy Zymogenetics for $885 Million
  • Drug Company Zogenix Plans Initial Public offering
  • Karo Bio Announces That Merck Discontinues Development Of MK-6913 For Hot Flashes
  • Bristol-Myers Squibb to Acquire ZymoGenetics
  • Police arrest two on drug charges
  • Martinez City Council candidates square off
  • Prince of pot’s jailer opposes drug laws
  • Merck schizophrenia drug approved for …

• Categories

  • News

• Monthly Archives

  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • December 1969

• Blogroll

  • Attorney Daily » Drug Injury News
  • Dangerous Drug Lawyer
  • Drugs.com - Pharma News
  • Health Canada RSS - Media Room
  • Lawyers and Settlements :: Drugs/Medical
  • Medication News
  • MedWatch Safety Alert RSS Feed

• Admin

  • Register
  • Log in
  • XHTML

Copyright © 2010 Drug Injury News